Analyst Price Targets — PEPG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 12:40 pm | Laura Chico | Wedbush | $4.00 | $1.62 | TheFly | PepGen price target lowered to $4 from $5 at Wedbush |
| February 18, 2026 12:25 pm | Debjit Chattopadhyay | Guggenheim | $7.00 | $6.79 | TheFly | PepGen price target raised to $7 from $6 at Guggenheim |
| October 28, 2025 11:16 am | Andrew Fein | H.C. Wainwright | $18.00 | $5.28 | TheFly | PepGen price target raised to $18 from $12 at H.C. Wainwright |
| September 25, 2025 5:06 pm | — | Stifel Nicolaus | $12.00 | $5.88 | TheFly | PepGen price target raised to $12 from $9 at Stifel |
| September 25, 2025 12:03 pm | — | Wedbush | $9.00 | $5.88 | TheFly | PepGen price target raised to $9 from $7 at Wedbush |
| December 21, 2022 6:26 am | — | H.C. Wainwright | $26.00 | $14.51 | Benzinga | HC Wainwright & Co. Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $26 |
| November 10, 2022 1:35 pm | — | Leerink Partners | $33.00 | $12.50 | Benzinga | SVB Leerink Maintains Outperform on PepGen, Lowers Price Target to $33 |
Latest News for PEPG
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy…
PepGen (PEPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2026, and recent corporate highlights. "We made encouraging progress during…
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PEPG.
U.S. House Trading
No House trades found for PEPG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.